WP
GPCR icon

Woodline Partners’s Structure Therapeutics GPCR Stock Holding History

Woodline Partners’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.25M Sell
153,808
-37,000
-19% -$1.64M 0.03% 577
2026
Q1 		$9.2M Buy
190,808
+66,906
+54% +$4.58M 0.03% 531
2025
Q4 		$8.62M Buy
123,902
+58,462
+89% +$2.39M 0.03% 496
2025
Q3 		$1.83M Sell
65,440
-111,013
-63% -$2.21M 0.01% 737
2025
Q2 		$3.66M Buy
176,453
+1,029
+0.6% +$22.6K 0.02% 617
2025
Q1 		$3.04M Sell
175,424
-158,477
-47% -$3.88M 0.02% 605
2024
Q4 		$9.06M Buy
333,901
+2,328
+0.7% +$82.6K 0.06% 368
2024
Q3 		$14.6M Sell
331,573
-5,828
-2% -$225K 0.12% 233
2024
Q2 		$13.2M Buy
337,401
+157,509
+88% +$6.47M 0.13% 218
2024
Q1 		$7.71M Buy
179,892
+673
+0.4% +$28.4K 0.07% 306
2023
Q4 		$7.3M Buy
179,219
+9,219
+5% +$528K 0.08% 265
2023
Q3 		$8.57M Hold
170,000
– – 0.1% 243
2023
Q2 		$7.07M Hold
170,000
– – 0.08% 253
2023
Q1 		$4.04M Buy
+170,000
New +$3.99M 0.06% 321

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Woodline Partners's GPCR Position: Q2 2026 in Review

Woodline Partners reduced its Structure Therapeutics (GPCR) stake by 19% in Q2 2026, selling an estimated $1.64M and leaving 153,808 shares worth $8.25M. The position accounts for 0.03% of the portfolio, ranked #577.

Woodline Partners first reported a position in GPCR in Q1 2023 and has held it in 14 quarters since. The position peaked at $14.6M in Q3 2024. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Woodline Partners held 153,808 shares of Structure Therapeutics worth $8.25M as of Q2 2026.
  • Woodline Partners sold 37,000 Structure Therapeutics shares in Q2 2026, an estimated $1.64M.
  • Structure Therapeutics made up 0.03% of Woodline Partners's portfolio in Q2 2026, its #577 holding.
  • Woodline Partners first reported a position in Structure Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Woodline Partners's Structure Therapeutics position peaked at $14.6M in Q3 2024.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.